Adenoviral Gene Delivery to Solid Tumors by Recombinant Silk–Elastinlike Protein Polymers

PurposeThe purpose of this study was to investigate the potential of silk–elastinlike protein polymers (SELPs) in controlling the release rate of adenoviruses in vitro and in vivo while preserving their bioactivity.Materials and MethodsA hydrogel system composed of SELP/adenovirus mixture was prepared. The release of the adenovirus particles from the hydrogels was quantified by Real Time-PCR and the bioactivity of the released viruses was evaluated using confocal microscopy and β-galactosidase assay. To demonstrate the ability of SELP in entrapping virus cargo and releasing it over a prolonged period of time in vivo, a SELP/adenovirus mixture was prepared and injected directly into xenograft tumor models of breast and head and neck cancer in mice. At various time points mice were sacrificed, tumors dissected, and tissue sections studied under confocal microscope.ResultsIn vitro studies demonstrated that SELP hydrogels release viruses over a period of 4 weeks while preserving their bioactivity. After intratumoral injection, a prolonged and localized expression of adenoviruses was observed.ConclusionsThese results suggest the potential of SELPs in local adenoviral delivery to solid tumors as an alternative approach to intratumoral virus infusion.

[1]  A. Söling,et al.  Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 Gene – A Phase I/II Clinical Protocol , 2004, Journal of Neuro-Oncology.

[2]  Lieven Thorrez,et al.  Preclinical gene therapy studies for hemophilia using adenoviral vectors. , 2004, Seminars in thrombosis and hemostasis.

[3]  Yong Wang,et al.  Systemic dissemination of viral vectors during intratumoral injection. , 2003, Molecular cancer therapeutics.

[4]  M. Marquet,et al.  Genetic Engineering of Structural Protein Polymers , 1990, Biotechnology progress.

[5]  K. Leong,et al.  Coacervate microspheres as carriers of recombinant adenoviruses , 1999, Cancer Gene Therapy.

[6]  L. Duan,et al.  Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Prieto,et al.  Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. , 2006, Cancer research.

[8]  W. Rom,et al.  Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. , 2003, Human gene therapy.

[9]  Milton W. Taylor,et al.  Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Hamidreza Ghandehari,et al.  Controlled Release of Plasmid DNA from a Genetically Engineered Silk-Elastinlike Hydrogel , 2002, Pharmaceutical Research.

[11]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[12]  Kinam Park,et al.  Controlled drug delivery : challenges and strategies , 1997 .

[13]  Y. Kaneda,et al.  The Efficacy and Safety of Gene Transfer into the Porcine Liver In Vivo by HVJ (Sendai Virus) Liposome , 2005, Transplantation.

[14]  M. Herlyn,et al.  FGF2-Targeted adenovirus encoding platelet-derived growth factor-B enhances de novo tissue formation. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Yong Wang,et al.  Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery , 2006, Molecular Cancer Therapeutics.

[16]  F. Yuan,et al.  Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.

[17]  A. Söling,et al.  Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 gene – a phase I/II Clinical Protocol , 2003, Journal of Neuro-Oncology.

[18]  Hamidreza Ghandehari,et al.  Swelling behavior of a genetically engineered silk-elastinlike protein polymer hydrogel. , 2002, Biomaterials.

[19]  Jie Xu,et al.  Transductional Protein-based Polymers as New Controlled Release Vehicles: ACS Professional Reference Books , 1997 .

[20]  M. Haider,et al.  Recombinant polymers for cancer gene therapy: a minireview. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[21]  F. Yuan,et al.  A novel method for viral gene delivery in solid tumors. , 2005, Cancer research.

[22]  Mansoor M. Amiji,et al.  Polymeric Gene Delivery : Principles and Applications , 2004 .

[23]  L. Naldini,et al.  Oncoretroviral and lentiviral vector-mediated gene therapy. , 2002, Methods in enzymology.

[24]  H. Ghandehari,et al.  Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. , 2002, Advanced drug delivery reviews.

[25]  Hamidreza Ghandehari,et al.  In vitro and in vivo evaluation of recombinant silk-elastinlike hydrogels for cancer gene therapy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.